Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Clear Cell Renal Cell CarcinomaClear Cell Renal Cell Carcinoma Metastatic
Interventions
DRUG

Selenomethionine (SLM)

Selenium (Se) is a natural element present in the earth's crust often in association with sulfur-containing compounds. Humans get their dietary requirements mainly from food. In this study Selenium will be administered in the chemical composition of selenomethionine (SLM)

DRUG

Axitinib

Axitinib is a small molecule tyrosine kinase inhibitor.

DRUG

Pembrolizumab

Pembrolizumab is a type of immunotherapy

Trial Locations (1)

52242

RECRUITING

University of Iowa Hospitals & Clinics, Iowa City

All Listed Sponsors
collaborator

University of Iowa

OTHER

lead

Mohammed Milhem

OTHER